Nowe leki w EU – co nowego z Europejskiej Agencji Leków (EMA)
Journal Title: Alergia - Year 2018, Vol 0, Issue 2
Abstract
received a positive opinion in the years 2017 – 2018 by the CHMP of the EMA are discussed. ............................... Omówiono najnowsze produkty lecznicze zaopiniowane pozytywnie przez CHMP Europejskiej Agencji Leków w latach 2017 - 2018. Wybrano te leki które znalazły zastosowanie w leczeniu POChP, kwasochłonnego zapalenia przełyku oraz atopowego zapalenia skóry.
Authors and Affiliations
Michał Pirożyński
Keywords
Related Articles
- EP ID EP463204
- DOI -
- Views 146
- Downloads 0
Wieloczynnikowa wrażliwość na czynniki chemiczne - problem nękający alergologów II.
The medical community including allergologists is confronted with heterogenous group of disabled conditions or diseases probably associated with exposure to antropogenic environmental factors. This group comprised of mul...
Alergiczne testy skórne punktowe – w kierunku obiektywizacji oceny wyniku
The paper presents the current rules for the implementation and interpretation of skin prick tests (SPT), with particular regard to methods that objectify the SPT score. Attention was paid to the PRICK-Film System - a mo...
Rola mikrobiomuw chorobachalergicznych
The results of epidemiological studies indicated the relationship between the individual development and the environmental exposure on the progression of allergic diseases and suggesting the role of microbiota in the pat...
Zespół niedoboru diaminooksydazy nowe aspekty diagnostyki i leczenia
Histamine plays an important role as a neurotransmitter in diverse brain functions and other part of body. The role of ingested histamine-below the level for intoxication-is discussed controversially. It has been suggest...
Negatywne skutki zdrowotne ekspozycji na smog: synopsis
Ambient air pollution is a well known public health hazard and is viewed as the world’s largest environmental health risk factor. The article provides short overview of the nature of atmospheric air pollution and their n...